TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF EUROPE VISCOSUPPLEMENTATION MARKET 24
1.4 CURRENCY AND PRICING 26
1.5 LIMITATIONS 26
1.6 MARKETS COVERED 26
2 MARKET SEGMENTATION 29
2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 DBMR TRIPOD DATA VALIDATION MODEL 31
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.6 MULTIVARIATE MODELLING 35
2.7 MARKET APPLICATION COVERAGE GRID 36
2.8 SOURCE LIFELINE CURVE 37
2.9 DBMR MARKET POSITION GRID 38
2.10 VENDOR SHARE ANALYSIS 40
2.11 SECONDARY SOURCES 41
2.12 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHT 45
4.1 PESTEL 46
4.2 PORTER'S FIVE FORCES MODEL 47
5 KEY SUCCESS FACTORS BY COUNTRY 48
5.1 GERMANY 48
5.2 FRANCE 49
5.3 U.K. 49
5.4 ITALY 50
5.5 RUSSIA 50
5.6 SPAIN 51
5.7 NETHERLANDS 51
5.8 SWITZERLAND 51
5.9 TURKEY 52
5.10 POLAND 53
5.11 AUSTRIA 53
5.12 PORTUGAL 53
6 REIMBURSEMENT SCENARIO, BY COUNTRY 54
6.1 GERMANY 54
6.2 FRANCE 54
6.3 U.K. 54
6.4 ITALY 54
6.5 RUSSIA 55
6.6 SPAIN 55
6.7 TURKEY 55
6.8 NETHERLANDS 55
6.9 SWITZERLAND 55
6.10 POLAND 56
6.11 HUNGARY 56
6.12 AUSTRIA 56
6.13 NORWAY 56
6.14 IRELAND 56
6.15 PORTUGAL 57
7 EPIDEMIOLOGY 58
8 INDUSTRIAL INSIGHTS 59
9 EUROPE VISCOSUPPLEMENTATION MARKET: REGULATIONS 60
10 MARKET OVERVIEW 62
10.1 DRIVERS 64
10.1.1 RISING GERIATRIC POPULATION 64
10.1.2 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS 64
10.1.3 TECHNOLOGICAL ADVANCEMENT IN VISCOSUPPLEMENTATION 64
10.2 RESTRAINTS 65
10.2.1 LACK OF TECHNICAL EXPERTISE 65
10.2.2 PRODUCT RECALL PROCEDURES 65
10.2.3 LIMITED APPLICATIONS OF VISCOSUPPLEMENTATION 66
10.3 OPPORTUNITIES 66
10.3.1 SAFETY AND EFFECTIVENESS OF INTRA-ARTICULAR HYALURONIC ACID (IAHA) 66
10.3.2 RISING HEALTHCARE EXPENDITURE 66
10.3.3 INCREASE IN DEMAND FOR MINIMALLY INVASIVE PROCEDURES 67
10.3.4 INCREASING NUMBER OF JOINT REPLACEMENTS AND SPORTS ACCIDENT 67
10.4 CHALLENGES 68
10.4.1 STRINGENT GOVERNMENT POLICIES FOR THE USE OF VISCOSUPPLEMENTATION 68
10.4.2 SIDE-EFFECTS OF VISCOSUPPLEMENTATION 68
11 EUROPE VISCOSUPPLEMENTATION MARKET, BY SOURCE 69
11.1 OVERVIEW 70
11.2 NON-ANIMAL ORIGIN 73
11.2.1 DUROLANE 74
11.2.2 EUFLEXXA 74
11.2.3 ORTHOVISC 74
11.2.4 MONOVISC 74
11.2.5 CINGAL 74
11.2.6 VISCOSEAL 74
11.2.7 OSTEONIL 74
11.2.8 OTHERS 74
11.3 ANIMAL ORIGIN 75
11.3.1 HYLAN G-F 20 76
11.3.2 SYNVIC ONE 76
11.3.3 SYNVISC 76
11.3.4 OTHERS 76
11.3.5 HYALURONANS 77
11.3.6 HYALGAN 77
11.3.7 OTHERS 77
12 EUROPE VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT 78
12.1 OVERVIEW 79
12.2 INTERMEDIATE MOLECULAR WEIGHT 82
12.2.1 DUROLANE 82
12.2.2 EUFLEXXA 82
12.2.3 ORTHOVISC 83
12.2.4 MONOVISC 83
12.2.5 VISCOSEAL 83
12.2.6 OSTEONIL 83
12.2.7 OTHERS 83
12.3 HIGH MOLECULAR WEIGHT 83
12.3.1 SYNVIC ONE 84
12.3.2 SYNVIC 84
12.3.3 OTHERS 84
12.4 LOW MOLECULAR WEIGHT 84
12.4.1 HYLAGAN 85
12.4.2 CINGAL 85
12.4.3 OTHERS 85
13 EUROPE VISCOSUPPLEMENTATION MARKET, BY INJECTION 86
13.1 OVERVIEW 87
13.2 SINGLE INJECTION 90
13.3 THREE INJECTION 90
13.4 FIVE INJECTION 91
14 EUROPE VISCOSUPPLEMENTATION MARKET, BY AGE GROUP 92
14.1 OVERVIEW 93
14.2 GERIATRIC 96
14.3 ADULTS 96
15 EUROPE VISCOSUPPLEMENTATION MARKET, BY END USER 97
15.1 OVERVIEW 98
15.2 HOSPITALS 101
15.3 ORTHOPEDIC CLINICS 101
15.4 AMBULATORY CARE CENTERS 102
15.5 OTHERS 102
16 EUROPE VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL 103
16.1 OVERVIEW 104
16.2 DIRECT TENDER 107
16.3 RETAIL SALES 107
17 EUROPE VISCOSUPPLEMENTATION MARKET, BY REGION 108
17.1 GERMANY 113
17.2 FRANCE 118
17.3 U.K. 123
17.4 ITALY 128
17.5 RUSSIA 133
17.6 SPAIN 138
17.7 TURKEY 143
17.8 NETHERLANDS 149
17.9 SWITZERLAND 154
17.10 POLAND 160
17.11 HUNGARY 166
17.12 AUSTRIA 172
17.13 NORWAY 177
17.14 IRELAND 182
17.15 PORTUGAL 187
17.16 REST OF EUROPE 193
18 EUROPE VISCOSUPPLEMENTATION MARKET: COMPANY LANDSCAPE 194
18.1 COMPANY SHARE ANALYSIS: EUROPE 194
19 COMPANY PROFILE 195
19.1 JOHNSON & JOHNSON SERVICES, INC. 195
19.1.1 COMPANY SNAPSHOT 195
19.1.2 REVENUE ANALYSIS 195
19.1.3 PRODUCT PORTFOLIO 196
19.1.4 RECENT DEVELOPMENTS 196
19.2 SANOFI-AVENTIS U.S. LLC 197
19.2.1 COMPANY SNAPSHOT 197
19.2.2 REVENUE ANALYSIS 197
19.2.3 PRODUCT PORTFOLIO 198
19.2.4 RECENT DEVELOPMENTS 198
19.3 FERRING B.V. 199
19.3.1 COMPANY SNAPSHOT 199
19.3.2 PRODUCT PORTFOLIO 199
19.3.3 RECENT DEVELOPMENT 199
19.4 ZIMMER BIOMET 200
19.4.1 COMPANY SNAPSHOT 200
19.4.2 REVENUE ANALYSIS 200
19.4.3 PRODUCT PORTFOLIO 201
19.4.4 RECENT DEVELOPMENTS 201
19.5 SEIKAGAKU CORPORATION 202
19.5.1 COMPANY SNAPSHOT 202
19.5.2 REVENUE ANALYSIS 202
19.5.3 PRODUCT PORTFOLIO 203
19.5.4 RECENT DEVELOPMENTS 203
19.6 ANIKA THERAPEUTICS, INC. 204
19.6.1 COMPANY SNAPSHOT 204
19.6.2 REVENUE ANALYSIS 204
19.6.3 PRODUCT PORTFOLIO 205
19.6.4 RECENT DEVELOPMENTS 205
19.7 APTISSEN 206
19.7.1 COMPANY SNAPSHOT 206
19.7.2 PRODUCT PORTFOLIO 206
19.7.3 RECENT DEVELOPMENT 206
19.8 BIOVENTUS 207
19.8.1 COMPANY SNAPSHOT 207
19.8.2 REVENUE ANALYSIS 207
19.8.3 PRODUCT PORTFOLIO 208
19.8.4 RECENT DEVELOPMENTS 208
19.9 FIDIA FARMACEUTICI S.P.A 209
19.9.1 COMPANY SNAPSHOT 209
19.9.2 REVENUE ANALYSIS 209
19.9.3 PRODUCT PORTFOLIO 210
19.9.4 RECENT DEVELOPMENT 210
19.10 IBSA INSTITUT BIOCHIMIQUE SA 211
19.10.1 COMPANY SNAPSHOT 211
19.10.2 PRODUCT PORTFOLIO 211
19.10.3 RECENT DEVELOPMENT 211
19.11 LG CHEM. 212
19.11.1 COMPANY SNAPSHOT 212
19.11.2 REVENUE ANALYSIS 212
19.11.3 PRODUCT PORTFOLIO 213
19.11.4 RECENT DEVELOPMENTS 213
19.12 TEVA PHARMACEUTICAL INDUSTRIES LTD. 214
19.12.1 COMPANY SNAPSHOT 214
19.12.2 REVENUE ANALYSIS 214
19.12.3 PRODUCT PORTFOLIO 215
19.12.4 RECENT DEVELOPMENTS 215
19.13 TRB CHEMEDICA SA 216
19.13.1 COMPANY SNAPSHOT 216
19.13.2 PRODUCT PORTFOLIO 216
19.13.3 RECENT DEVELOPMENTS 216
19.14 VIATRIS INC. 218
19.14.1 COMPANY SNAPSHOT 218
19.14.2 REVENUE ANALYSIS 218
19.14.3 PRODUCT PORTFOLIO 219
19.14.4 RECENT DEVELOPMENTS 219
20 QUESTIONNAIRE 220
21 RELATED REPORTS 223

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.